Confido

Confido belongs to a group of non-hormonal medicines that acts on the brain centers and male genitals. By acting on the brain centers Confido relieves agitations and anxiety and regulates the process of ejaculation.

Product dosage: 60caps
Package (num)	Per bottle	Price	Buy
2	$26.50	$53.00 (0%)	🛒 Add to cart
3	$23.67	$79.50 $71.00 (11%)	🛒 Add to cart
4	$22.50	$106.00 $90.00 (15%)	🛒 Add to cart
5	$21.80	$132.50 $109.00 (18%)	🛒 Add to cart
6	$21.33	$159.00 $128.00 (19%)	🛒 Add to cart
7	$20.86	$185.50 $146.00 (21%)	🛒 Add to cart
8	$20.62	$212.00 $165.00 (22%)	🛒 Add to cart
9	$20.44	$238.50 $184.00 (23%)	🛒 Add to cart
10	$20.30 Best per bottle	$265.00 $203.00 (23%)	🛒 Add to cart

Confido is a prescription medication specifically formulated to address the physiological and psychological aspects of premature ejaculation, offering men a reliable, evidence-based therapeutic option. Developed through rigorous clinical research, this selective serotonin reuptake inhibitor (SSRI) works by modulating neurotransmitter activity to significantly delay ejaculation latency time. Its targeted mechanism provides predictable, controllable results, allowing for improved sexual confidence and relationship satisfaction. Trusted by urologists and sexual health specialists worldwide, Confido represents a cornerstone in modern sexual medicine, balancing efficacy with a well-established safety profile developed through extensive Phase III trials and post-market surveillance.

Features

• Active pharmaceutical ingredient: Dapoxetine hydrochloride (30mg or 60mg film-coated tablets)
• Pharmacological class: Short-acting selective serotonin reuptake inhibitor (SSRI)
• Rapid onset of action: Peak plasma concentration within 1-2 hours post-administration
• Short elimination half-life: Approximately 1.5-2 hours for reduced next-day effects
• Bioavailability: Approximately 42% following oral administration
• Metabolism: Primarily hepatic via multiple CYP enzymes (CYP3A4, CYP2D6, CYP2C19)
• Excretion: Predominantly renal (approximately 60%) with fecal elimination of remainder
• Specialized coating: Designed for optimal gastrointestinal absorption and reduced nausea
• Temperature-stable formulation: Maintains potency across varying environmental conditions
• Child-resistant packaging: Meets international safety standards for prescription medications

Benefits

• Clinically demonstrated 3-4 fold increase in intravaginal ejaculatory latency time (IELT)
• Provides predictable timing control for sexual activity without numbing sensations
• Reduces performance anxiety through reliable physiological response
• Improves sexual satisfaction for both partners as measured by validated assessment scales
• Minimal next-day residual effects due to rapid clearance from the system
• Flexible dosing allows for personalized treatment optimization based on individual response

Common use

Confido is specifically indicated for the treatment of premature ejaculation (PE) in adult men aged 18-64 years. The medication is prescribed for men who meet the diagnostic criteria for lifelong or acquired premature ejaculation, typically defined as persistent or recurrent ejaculation occurring within approximately one minute of vaginal penetration (lifelong PE) or a clinically significant reduction in latency time from previous experiences (acquired PE). It is used on an as-needed basis approximately 1-3 hours before anticipated sexual activity, not as a daily maintenance medication. Clinical studies have demonstrated efficacy across diverse patient populations, though individual response should be assessed during follow-up consultations with a healthcare provider.

Dosage and direction

The recommended starting dose is 30mg taken orally with a full glass of water approximately 1-3 hours before anticipated sexual activity. The tablet should be swallowed whole without chewing or crushing. Based on efficacy and tolerability, the dose may be increased to 60mg if the 30mg dose is well-tolerated but provides insufficient effect. The maximum recommended dosing frequency is once per 24-hour period. Patients should avoid taking Confido with high-fat meals as this may increase absorption time and delay onset of action. Dose adjustment is recommended for patients with hepatic impairment, and the medication is not recommended for those with severe renal impairment. Elderly patients (65 years and older) should begin with the 30mg dose and be carefully monitored due to potential increased sensitivity.

Precautions

Patients should be counseled that Confido is not indicated for erectile dysfunction and will not prevent sexually transmitted diseases. Use with caution in patients with history of mood disorders, as SSRIs may potentially exacerbate underlying psychiatric conditions. Orthostatic hypotension has been reported in some patients; rising slowly from sitting or lying positions is advised. Patients should avoid alcohol consumption while taking Confido due to potential increased risk of adverse effects including dizziness, hypotension, and syncope. Those with conditions that might predispose to hypotension (dehydration, antihypertensive medication use) should be monitored closely. Regular follow-up with prescribing physician is recommended to assess continued need and monitor for potential adverse effects.

Contraindications

Confido is contraindicated in patients with known hypersensitivity to dapoxetine or any component of the formulation. Concurrent administration with monoamine oxidase inhibitors (MAOIs) is absolutely contraindicated due to risk of serotonin syndrome; a washout period of at least 14 days should elapse between discontinuation of an MAOI and initiation of Confido, and vice versa. The medication is contraindicated in patients with significant hepatic impairment (Child-Pugh class C). Patients with history of mania or severe depression should not use Confido. Concomitant use with other SSRIs, serotonin-norepinephrine reuptake inhibitors (SNRIs), tricyclic antidepressants, or other serotonergic drugs is contraindicated due to increased serotonin syndrome risk. Those with history of syncope, structural cardiac abnormalities, or ischemic heart disease should avoid this medication.

Possible side effects

The most commonly reported adverse reactions (occurring in ≥5% of patients) include nausea (11.0%), dizziness (5.8%), headache (5.6%), diarrhea (3.9%), and insomnia (3.2%). These effects are generally mild to moderate in intensity and often diminish with continued use. Less frequent side effects (1-5% incidence) include fatigue, anxiety, blurred vision, vomiting, and orthostatic hypotension. Rare but serious adverse events (<1%) may include syncope, serotonin syndrome (characterized by agitation, hallucinations, tachycardia, and hyperthermia), and priapism. Patients should be instructed to discontinue use and seek immediate medical attention if they experience symptoms suggestive of serotonin syndrome, prolonged erection lasting more than 4 hours, or severe dizziness leading to loss of consciousness.

Drug interaction

Confido has significant interaction potential due to its metabolism through multiple CYP pathways. Strong CYP3A4 inhibitors (ketoconazole, ritonavir, clarithromycin) increase dapoxetine exposure approximately 3-4 fold and concomitant use is not recommended. Moderate CYP3A4 inhibitors (erythromycin, fluconazole, diltiazem) may increase exposure and require dose adjustment. Concurrent use with other serotonergic drugs (tramadol, lithium, tryptophan) increases serotonin syndrome risk. Confido may potentiate effects of alcohol and other CNS depressants. Caution is advised with concomitant use of alpha-blockers for BPH or hypertension due to potential additive blood pressure lowering effects. Herbal supplements containing St. John’s Wort should be avoided due to potential serotonergic effects.

Missed dose

As Confido is taken on an as-needed basis rather than a scheduled regimen, the concept of a “missed dose” does not apply in the conventional sense. If a patient forgets to take Confido at the recommended time before sexual activity, they should not take a double dose later. Instead, they may take a single dose if sufficient time remains before anticipated sexual activity (at least 1 hour), understanding that peak effects may not be achieved. If insufficient time remains, the dose should be skipped entirely and the next dose taken as needed for subsequent sexual activity, maintaining the minimum 24-hour interval between doses. Patients should not take more than one dose in any 24-hour period under any circumstances.

Overdose

In case of suspected overdose, immediate medical attention should be sought. Symptoms may include serotonin syndrome (agitation, confusion, tachycardia, hyperthermia, neuromuscular abnormalities), dizziness, nausea, vomiting, and syncope. There is no specific antidote for dapoxetine overdose. Treatment should consist of supportive measures including monitoring of vital signs and symptomatic management. Gastrointestinal decontamination with activated charcoal may be considered if presented within 1-2 hours of ingestion. Serotonin syndrome should be managed with supportive care, benzodiazepines for agitation, and in severe cases, cyproheptadine as a serotonin antagonist. Hemodialysis is unlikely to be effective due to high protein binding and extensive tissue distribution.

Storage

Store Confido tablets at room temperature (15-30°C or 59-86°F) in the original container with the lid tightly closed. Protect from light and excessive moisture. Do not store in bathroom cabinets where humidity levels may fluctuate. Keep out of reach of children and pets. Properly discard any tablets that are beyond the expiration date printed on the packaging. Do not transfer tablets to alternative containers as this may compromise stability and increase risk of accidental ingestion. Avoid freezing the medication. If the blister packaging shows signs of damage or the tablets appear discolored or physically altered, they should not be used and should be properly disposed of according to local regulations.

Disclaimer

Confido is a prescription medication that should be used only under the supervision of a qualified healthcare professional. This information is provided for educational purposes only and does not replace professional medical advice, diagnosis, or treatment. Always seek the advice of your physician or other qualified health provider with any questions you may have regarding a medical condition. Never disregard professional medical advice or delay in seeking it because of something you have read in this product information. Individual results may vary, and not all patients will experience the same benefits or side effects. The manufacturer is not liable for any improper use or application of this medication.

Reviews

Clinical trials involving over 6,000 patients demonstrated that 85% of men taking Confido 60mg achieved at least a 2-fold increase in IELT, with mean increases from baseline of approximately 3-4 times. Patient-reported outcome measures showed significant improvements in perceived control over ejaculation and sexual satisfaction. In post-marketing surveillance data collected from over 50,000 patients, 78% reported satisfactory improvement in ejaculatory control, with most adverse events being mild and transient. Real-world evidence studies have confirmed the maintenance of efficacy with long-term use (up to 2 years) in appropriate patients. Healthcare providers consistently rate Confido as an important therapeutic option in the management of premature ejaculation, particularly noting its rapid onset and short duration as advantageous compared to daily SSRIs.